Close Menu

People in the News

Aug 13, 2020

Myriad Genetics: Paul Diaz

Myriad Genetics has appointed Paul Diaz as its new president and CEO, effective Aug. 13, 2020. Diaz, who will also serve on Myriad's board of directors, will take over from Bryan Riggsbee, who has been serving as the company's interim president and CEO, and CFO after Mark Capone's resignation from that post in February. Diaz served as president, CEO, and in various other roles at Kindred Healthcare, a provider of post-acute healthcare services, for more than a decade. He was also a partner at the private equity firm Cressey & Company LP, and has served as an executive and board member at multiple public and private companies. He is currently on the board of DaVita and a member of the board of trustees of Johns Hopkins Medicine. 

Aug 07, 2020

Pacific Biosciences: Christian Henry, Michael Hunkapiller, John Milligan, Ben Gong

Pacific Biosciences has appointed Christian Henry as president and CEO effective Sept. 14, 2020. Henry has served on the board of directors since 2018, including as chairman since March 2020.

John Milligan, a board member since 2013, has been appointed to succeed Henry as chairman, also effective Sept. 14.

As previously announced, Michael Hunkapiller will retire from an active operating role at the end of the year. Effective Sept. 14, Hunkapiller will assume the position of senior fellow focused on technology development until his retirement. Hunkapiller will also continue to serve on the company's board.

In addition, Pacific Biosciences has named Ben Gong as interim CFO to succeed Susan Barnes, who's retirement from the position was previously announced.

Aug 07, 2020

Tangen Biosciences: Vance Kershner, Alan Levin

Tangen Biosciences has appointed Vance Kershner and Alan Levin to its board of directors in conjunction with a $12.2 million Series B preferred stock financing. Kershner is founder, president, and CEO of LabWare, which develops and implements software for automating laboratory operations. Levin previously served as president and CEO of drugstore chain Happy Harry's, which merged with the Walgreen Company in 2006. Levin also previously served as the Director of the Delaware Economic Development Office.

Aug 06, 2020

Crown Bioscience: John Gu

Crown Bioscience has been appointed John Gu as chief operations officer. Gu joins Crown Bio from WuXi Nextcode, where he was general manager for the China business and chief digital officer. Prior to WuXi, Gu was held successive senior technology and operations roles across digital and technology companies, including Alcatel-Lucent. 

Aug 05, 2020

Integrity Laboratories: Maria Cekanova

Integrity Laboratories has appointed Maria Cekanova CSO. She was previously director of translational research laboratory and research associate professor of oncology in the department of small animal clinical sciences at the University of Tennessee. Integrity recently received Emergency Use Authorization from the US Food and Drug Administration for its SARS-CoV-2 Assay.

Aug 04, 2020

Lexogen: Stéphane Barges, Alexander Seitz

Sequencing firm Lexogen has appointed Stéphane Barges as CEO, effective Sept. 1. 

Barges comes to Lexogen from Qiagen, where he was VP of molecular diagnostics. He has 20 years of experience in the life science and clinical diagnostics industry, including management positions at Life Technologies, Bio-Rad Laboratories, and Tecan. He holds a doctorate in genetics and molecular biology from the University of Geneva and an MBA from HEC Geneva.

Barges will succeed Lexogen founder Alexander Seitz, who will take on the role of chief innnovation officer.

Jul 31, 2020

Talis Biomedical: Roger Moody, Kim Popovits, Walter Koch

Talis Biomedical has named Roger Moody as CFO, while Kim Popovits has joined the company's board and Walter Koch has joined its scientific advisory board.

Moody was formerly CFO of Clinical Genomics. He previously was chief executive and COO at Glysure and CFO of Nanosphere and Medsn. Popovits is the former chairman of the board, president, and CEO of Genomic Health, which was acquired by Exact Sciences. She also held several management positions at Genentech, now part of Roche. Koch was at Roche Molecular Systems where he held several leadership roles, including vice president and head of global research. Prior to that, he was at the US Food and Drug Administration.

Jul 30, 2020

ACMG Foundation for Genetic and Genomic Medicine: Nasha Fitter

The ACMG Foundation for Genetic and Genomic Medicine, a national nonprofit foundation dedicated to facilitating the integration of genetics and genomics into medical practice, has elected Nasha Fitter to its board of directors. Fitter currently serves as director of Rare and Neurological Diseases at Ciitizen. She is also cofounder, CEO, and head of research at FOXG1 Research Foundation, an organization focused on finding a cure for FOXG1 syndrome. Previously, Fitter founded and served as CEO of Schoolie, and prior to that worked as director of the Global Schools Program at Microsoft Education.

Jul 29, 2020

Agendia: Brian Dow

Agendia has appointed Brian Dow as CFO. Prior to this position, he served as senior VP and CFO of Pulse Biosciences, where he was responsible for executing the company's early-stage IPO and subsequent follow-on offerings. Before that, he was CFO at Progyny, and prior to that, he was VP and principal accounting officer at Pacific Biosciences. Previously, he also worked for Ernst & Young. Dow holds a bachelor's degree from Georgia Institute of Technology.

Jul 28, 2020

Aegea Biotechnologies: George Maltzeos

Aegea Biotechnologies said that it has hired George Maltzeos as chief engineer to help expedite the development of the company's point-of-care lateral flow molecular SARS-CoV-2 test being developed in collaboration with Tauriga Sciences. Maltzeos previously served as director of the California Institute of Technology Global Health Initiative where he helped secure $4.5 million in funding from the Bill & Melinda Gates Foundation to develop point-of-care clinical diagnostics for developing countries. He also previously founded and served as chief engineer for Helixis, which was acquired by Illumina in 2010. Maltzeos holds a PhD in electrical engineering from CalTech and a BS from Columbia University.

Jul 28, 2020

Clinical Genomics: Michael Paris, Zivjena Vucetic, Edward Rosen

Clinical Genomics has appointed Michael Paris as chief operating officer, Zivjena Vucetic as senior VP, medical, and Edward Rosen as chief strategy and commercial officer.

Paris most recently served as COO and senior VP, operations and technology development, at Origin. Prior to Origin, he served in several positions at Bioconnect Systems, Orthovita, and Rex Medical. 

Before Clinical Genomics, Vucetic served as medical director at Ortho-Clinical Diagnostics. Prior to that, she held multiple scientific and medical roles at Fujirebio Diagnostics. 

Rosen most recently served as an executive in residence at Columbia University. Prior to Columbia, he held several research roles at Johnson & Johnson. 

Jul 28, 2020

Meridian Bioscience: Anthony Bihl

Meridian Bioscience announced the appointment of Anthony Bihl to its board of directors, effective immediately. Bihl retired in April as CEO of Bioventus and was previously the CEO of American Medical Systems and CEO of Siemens Medical Solutions Diagnostics. He has also served in senior executive roles at Bayer Healthcare's diagnostics division and in multiple operations and finance roles at Dupont.

Jul 27, 2020

Veracyte: Jens Holstein, James Erlinger

Veracyte has appointed Jens Holstein to its board of directors and James Erlinger as executive VP, general counsel, and secretary.

Holstein was appointed as CFO of MorphoSys in 2011. Prior to MorphoSys, he served as regional CFO of the Europe/Middle East region for Fresensius Kabi, a subsidiary of Fresenius. He has also held several other leadership roles within the Fresenius group. 

Erlinger previously served as executive VP, general counsel, and secretary of Iqvia. He spent the balance of his career as a partner of the international law firm of Bryan Cave Leighton Paisner. 

Jul 24, 2020

SeqBiome: Marcus Claesson, Paul Cotter, Brad Wrigley

University College Cork spinout SeqBiome announced its management team this week. Marcus Claesson is the company's CEO, Paul Cotter is the firm's chief technology officer, and Brad Wrigley is executive director.

Claesson is a principal investigator at APC Microbiome Ireland. He has a PhD in bioinformatics from the National University of Ireland and an MSc in bioinformatics, as well as a BSc in chemical engineering and physics, from Chalmers University of Technology in Gothenburg, Sweden.

Cotter is head of food biosciences at Teagasc and a principal investigator with APC Microbiome Ireland, Vistamilk SFI Centres, and Food for Health Ireland. He holds PhD and BSc degrees in microbiology from University College Cork.

Wrigley has been working with several startup and spinout companies. He has more than 20 years of experience as a director, entrepreneur, investor, and CEO in government and industry, including at Accenture, Dell EMC, and Virtustream.

Jul 24, 2020

Cradle Genomics: Tanya Moreno, Sue Gross

Prenatal diagnostics firm Cradle Genomics has appointed Tanya Moreno as VP of development and Sue Gross as chief medical officer.

Moreno has 13 years of experience in diagnostics development and the commercialization of genomic tests. She holds a PhD in molecular genetics and developmental biology from the California Institute of Technology.

Gross joins the company from Sema4, where she was medical director for the reproductive lab and clinical analysis division. Previously, she was chief medical officer at Natera, and before that, professor of obstetrics and gynecology, pediatrics, and genetics at Montefiore Einstein. She is a physician with board certifications in obstetrics and gynecology as well as medical genetics.

Jul 23, 2020

Twist Bioscience: Erin Smith

Twist Bioscience has appointed Erin Smith to the newly created position of senior VP of government affairs and public policy.

According to federal disclosure records, Smith registered as a lobbyist for Twist in December 2019, while at Smith Capitol Strategies. She is also an adjunct faculty member of the University of Houston Law Center.

Prior to Twist, Smith worked at Gilead Sciences, where she expanded the firm's lobbying efforts. Before that, she was an advisor to former Secretary of Energy and former Governor of Texas Rick Perry.

Smith holds a JD from the University of Houston Law Center and a master of public health degree from the University of Texas Health Science Center.

Jul 22, 2020

Myriad Genetics: Walter Gilbert, Daniel Skovronsky

Myriad Genetics has expanded its board of directors to 10 members with the election of Daniel Skovronsky, CSO and president of Lilly Research Laboratories at Eli Lilly. Skovronsky will serve on the research and product innovation committee within Myriad’s board. Additionally, Myriad announced that Walter Gilbert, the director and vice chair of the board, will retire from these positions at the firm's annual stockholder meeting in December. Gilbert cofounded Myriad and received a Nobel Prize in chemistry in 1980 for his development of rapid DNA sequencing technology. 

Jul 22, 2020

Biodesix: Jean Franchi, Hany Massarany

Biodesix has appointed Jean Franchi and Hany Massarany to its board of directors. Franchi has more than 30 years of biotechnology and life science industry experience ranging from pre-commercial to global commercial biotech operations. Massarany has extensive experience in the global diagnostics industry, with expertise in molecular diagnostic testing.

Franchi currently serves as chief financial officer for Replimune Group, a biotechnology company developing oncolytic immuno-gene therapies. She has led operational and financial strategy at several companies in domestic and international markets of various stages and sizes, including 16 years at Genzyme. She holds a bachelor's degree in business administration from Hofstra University.

Massarany served as president and chief executive officer of GenMark Diagnostics from 2011 to 2020. Prior to joining GenMark, he held the role of president at Ventana Medical Systems and head of Roche Tissue Diagnostics. From 1999 to 2009 he was responsible for various global leadership positions with Ventana. He has also held executive management positions with Bayer Diagnostics and Chiron Diagnostics. Massarany earned a bachelor’s degree in microbiology and immunology from Monash University and an MBA from Melbourne University.

Jul 20, 2020

Todos Medical: Priyanka Misra, Elise Brownell

Todos Medical has appointed Priyanka Misra VP of corporate development and Elise Brownell VP of R&D. Misra previously was a senior investment analyst at Feller Advisors. Prior to that, she was at Goldman Sachs Asset Management in the Alternative Investments and Manager Selection group. Brownell started her career at the State University of New York, Stony Brook before moving to Frederick Cancer Research Facility and Bayer Healthcare.

Jul 20, 2020

NeoGenomics:  Michael Kelly, Lynn Tetrault

NeoGenomics said Michael Kelly has joined its board of directors and Lynn Tetrault has been named lead independent director of the board.

Kelly joined the board on July 15 and will serve as a member of the audit committee. He is a former senior executive of Amgen and is currently acting as founder and president of Sentry Hill Partners. He has served in various strategic finance and operations positions at Amgen, most recently as senior vice president of global business services and VP and CFO of international commercial operations. Kelly has also held positions at Biogen, Tanox, and Monsanto Life Sciences.

Tetrault also assumed her new role as of July 15. She has served on the company’s board since June 2015 and is chair of the compensation committee. She founded Anahata Leadership, an advisory firm focused on supporting the leadership effectiveness of executive women. She worked from 1993 to 2014 with AstraZeneca, most recently on its global executive team as executive vice president of human resources and corporate affairs from 2007 to 2014. Prior to AstraZeneca, Tetrault practiced healthcare and corporate law at Choate, Hall and Stewart in Boston.

Jul 16, 2020

Personalis: Leslie Grab, John Lyle

Personalis has appointed Leslie Grab as VP of intellectual property and John Lyle as VP of assay research and development.

Grab joins the firm from Verily Life Sciences where she was responsible for worldwide patent and trademark strategy and portfolio development across multiple product areas. Prior to that, she worked at the law firm of Kilpatrick Townsend & Stockton. Grab holds a PhD in biochemistry and molecular biology from Wake Forest University and a BA in chemistry from Catawba College, North Carolina. She earned her law degree from the University of North Carolina, Chapel Hill, where she also served as a post-doctoral associate researching the inter-relationship between exosomes and ovarian cancer.

Lyle joins Personalis after 14 years at Pacific Biosciences where he most recently served as senior director of single-molecule sequencing, focusing on reagent, system, and application development of long-read, ultra-high accuracy sequencing. He received his PhD from Stanford University in microbiology and immunology and holds a BS from Bates College. Lyle also served as a post-doctoral fellow at the University of California, San Francisco, studying the structure and function of the centrosome.

Jul 16, 2020

HalioDx: Stéphane Debono, Philippe Mourere

HalioDx has appointed Stéphane Debono as deputy CEO and Philippe Mourere as senior VP of commercial and business development. Debono is a cofounder of HalioDx. Mourere most recently served as senior VP of commercial operations at Ultivue, a developer of tissue biomarker assays for translational research.  

Jul 14, 2020

Predictive Oncology: Nancy Chung-Welch, Charles Nuzum, Greg St. Clair

Predictive Oncology has appointed Nancy Chung-Welch, Charles Nuzum, and Greg St. Clair as independent directors. While Nuzum will serve on Predictive's audit committee, the firm noted that the other directors will join committees as soon as possible. 

Chung-Welch currently serves as an independent consultant advising life science companies and institutional investors. She previously served as director of business development at Cell Signaling Technology, as well as a director of business development at Thermo Fisher Scientific. She has also served as a technical marketing manager at Fisher Scientific.

Nuzum currently provides project-based financial consulting services to companies including McKesson, BioMarin, and AutoDesk. He serves on the board of directors of Dakshidin, NanoSynx, and Worldwide Structures. He previously cofounded and served as CFO of Tyburn Group. Prior to Tyburn, Nuzum served as controller of Merck KgaA pharmaceutical manufacturing subsidiary Dely. Before working at Dely, he served as cofounder, executive VP, and CFO of SCV Financial Services. 

St. Clair is the founder and managing member of SunStone Consulting. Prior to SunStone, he served as national VP of CGI, ImrGlobal, and Orion Consulting. He also served as a national director for Coopers & Lybrand. 

Jul 09, 2020

Teknova: Stephen Gunstream

Teknova has appointed Stephen Gunstream as its CEO. Gunstream will replace Ted Davis, the firm's founder and retiring CEO. Gunstream previously served as VP and general manager of BD Biosciences' research and clinical business. Prior to BD, Gunstream served as chief commercial officer at Integrated DNA Technologies.  

Jul 08, 2020

Notable: Joseph Wagner

Precision oncology company Notable has hired Joseph Wagner as CSO. A pharmacologist by training with a history in the biotech industry, Wagner had been executive director of the University of California Drug Discovery Consortium. He previously held executive positions at BriaCell Therapeutics, OncoCyte, and Cell Targeting. Wagner will report directly to Notable CEO Laurie Heilmann. 

Pages

A new analysis suggests warming, not the arrival of humans, led to the extinction of the woolly rhinoceros thousands of years ago, the Economist reports.

Chinese health officials uncovered SARS-CoV-2 viral RNA on imported frozen food, but the New York Times reports catching COVID-19 that way would be unlikely.

The UK has ordered 60 million coronavirus vaccine doses from Novavax and 30 million doses from Janssen, according to the Guardian.

In Science this week: machine learning model predicts whether ion channel mutations will cause disease, and more.